Evaluation of Radiprodil in Children With GRIN-related Disorder
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential
efficacy of radiprodil for the treatment of GRIN-related disorder in children with a
Gain-of-Function (GoF) genetic variant. Subjects' participation in the study is expected to
last up to six months.
The study is open-label, so all participants will be treated with radiprodil. After the end
of this study, all participants who are still eligible can choose to continue to receive
radiprodil as part of an open-label extension period.